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Hemofiltration in human sepsis: Evidence for elimination of immuno-
modulatory substances. Continuous hemofiltration is widely used for
renal replacement therapy in patients with acute renal failure. It has been
suggested that hemofiltration may also eliminate toxic mediators thought
to be important in the pathophysiology of sepsis. The present study
examined whether hemofiltration can activate or eliminate inflammatory
mediators in patients with sepsis, and whether ultrafiltrate can alter
specific functions of peripheral blood mononuclear leukocytes (PBMC) in
vitro. Veno-venous hemofiltration was performed in 16 patients and in 5
healthy volunteers. Pre-filter (afferent), post-filter (efferent) and ultrafil-
trate concentrations of cytokines (IL-113, IL-6, IL-8, TNFa) and of
complement components (C3, C3ades.g, C5adeArg, terminal complement
complex) were measured after the beginning of hemofiltration (t0), and 60
minutes later (t60). PBMC, and monocyte and lymphocyte subfractions
were incubated with ultrafiltrate, and cytokines were determined in the
supernatants. Hemofiltration did not induce significant mediator activa-
tion. There was no evidence for significant cytokine elimination. However,
pre-filter C3adesArg concentration showed a significant decline during
hemofiltration (patients: to = 676.9 99.7 ng/ml, t60 = 545.4 83.2, P <
0.001; volunteers: to = 54.8 13.3 ng/ml, t60 = 33.9 10.7, P < 0.001).
Ultrafiltrate from septic patients significantly stimulated PBMC and
monocyte TNFs release, but suppressed lymphocyte IL-2 and IL-6
production. Ultrafiltrate from volunteers was without effect. Hemofiltra-
tion effectively eliminates certain mediators such as C3adeg. Ultrafiltrate
contains compounds with significant immunomodulatoiy qualities. There-
fore, hemofiltration may represent a new modality for removal of immu-
nomodulatory mediators.
Multiple organ dysfunction syndrome is currently the leading
cause of death in patients with sepsis. To treat individual organ
failure, modern technology offers a variety of concepts to be used
in intensive care medicine. Besides artificial ventilation and
left-heart assisting devices, continuous renal replacement therapy
has gained prominence in the treatment of critically ill patients. In
recent years, the established procedure, intermittent hemodialy-
sis, is being superseded by various types of continuous renal
replacement therapy, including continuous arterio-venous hemo-
filtration, continuous veno-venous hemofiltration and continuous
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veno-venous hemodiafiltration. Continuous high volume hemofil-
tration has proven equally effective in controlling uremia, but
found to be superior to hemodialysis, because hemofiltration
results in fewer cardiovascular side effects [11. Furthermore,
continuous hemofiltration allows better control of fluid balance
and simultaneous continuation of total parenteral nutrition [2].
Recently, a new aspect of isovolemic hemofiltration has
emerged, namely, the possibility that it can eliminate inflamma-
tory mediators, considered important in the pathophysiology of
human sepsis [31. In a recent clinical study, we demonstrated a
correlation between the daily amount of ultrafiltrate and the
survival rate in critically ill patients with sepsis who simultaneously
had kidney failure [4]. Several animal studies indicate that
isovolemic hemofiltration may improve various organ functions
[5—8] or increase survival in sepsis and endotoxinemia [5, 6, 9, 10].
Correspondingly, toxic mediators (cytokines, cyclic endoperox-
ides) have been identified in ultrafiltrate from septic animals [9]
and patients [11]. However, the possibility that hemofiltration also
improves specific organ failure in human sepsis, is a point of
controversy. Additionally, the detoxif'ing mechanisms of hemo-
filtration in sepsis remain unclear. It has been argued that
mediators detected in septic ultrafiltrate, were only activated and
released into the ultrafiltrate by blood-filter contact. The latter
mechanism has been observed with certain dialysis membranes
[1].
It was the aim of the present study to examine whether
short-term hemofiltration can eliminate or activate established
mediators in human sepsis. To do this, we compared and analyzed
plasma and ultrafiltrate from patients with sepsis who simulta-
neously had multiple organ dysfunction, and from healthy con-
trols. We focused on those mediators (IL-1f3, IL-6, IL-8, TNFa,
and anaphylatoxins C3adesArg and CSadesg) of which plasma
concentration had been shown to correlate with patient outcome
and which are believed to play a pivotal role in the pathophysiol-
ogy of human sepsis [12, 131. We further characterized the specific
qualities of ultrafiltrate by exposing different subfractions of
mononuclear leukocytes to ultrafiltrates and by measuring several
aspects of cell function (cell proliferation and cytokine synthesis).
Methods
The studies were reviewed and approved by the local institu-
tional review board.
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Table 1. Clinical characteristics of patients with multiple organ
dysfunction due to a systemic inflammatory response syndrome
Score
Patient
No. Age Sex
points
(a) Diagnosis
Outcome
(b)
1 54 M 23 Esophagectomy,
mediastinitis
D
2 82 M 21 Short bowel syndrome,
pneumonia
D
3 68 M 21 Lung resection, pneumonia D
4 58 M 20 Empyema of the gall-
bladder, pneumonia
D
5 78 M 21 Abdominal aortic aneurysm
repair, pneumonia
D
6 55 M 23 Hernial repair, liver failure D
7 63 F 20 Lung resection
mediastinitis
D
8 77 M 23 Lung resection,
mediastinitis
D
9 47 F 22 Colon resection, peritonitis S
10 32 F 26 Pneumonia, liver failure D
11 69 M 22 Esophagectomy, aortic
rupture, ARDS
D
12 64 M 20 Esophagectomy, ARDS S
13 61 M 22 Bowel perforation,
peritonitis
D
14 81 M 23 Bowel perforation,
peritonitis
D
15 37 M 20 Necrotizing pancreatitis S
16 64 M 23 Nephrectomy, peritonitis D
Modified Elebute score according to Ref [15]
b 5 = survival; D = death
Subjects
Patients. Biochemical studies were conducted in 16 post-trau-
matic or postoperative patients (13 males, 3 females; age 60 3.8
years), who were admitted to the surgical intensive care unit at the
Munich University Hospital, Klinikum Grosshadern. All patients
were suffering from a septic multiple organ dysfunction syndrome,
as defined recently [14], and were scored daily by a slightly
modified Elebute sepsis score [15]. In addition to the original
score, bleeding diathesis from disseminated intravascular coagu-
lation was defined as follows: antithrombin III < 50% of control
value, INR < 2, fibrinogen < 1.5 g/liter, platelet count < 100
g/liter. At least three of these criteria must have been fulfilled to
achieve points in the absence of clinical bleeding diathesis. All
patients were mechanically ventilated and received conventional
therapy (ciystalloids, vasoactive agents and antibiotics). Three
patients had acute renal failure at the time of entry into the study.
When the patients reached a score of 20 or more Elebute points
(mean Elebute 22 0.4) they entered the study. The ages,
diagnoses, Elebute scores and outcomes are listed in Table 1.
Healthy volunteers. After informed consent was obtained, five
healthy scientists from our laboratory (4 males and 1 female,
mean age 37.4 4.3) received continuous hemofiltration, includ-
ing vascular access, low dose heparinization and continuous
monitoring under intensive care conditions (see below).
Study design
Continuous veno-venous hemofiltration was performed using
the Gambro hollow fiber hemofilter FH 66 D which contains a
highly permeable polyamide membrane (Gambro, Hechingen,
Germany). Vascular access was obtained via percutaneous punc-
ture of the femoral vein or the subclavian vein and by subsequent
insertion of a double-lumen Shaldon catheter. Hemofilters were
initially rinsed with 2 liters of Ringer's solution, including 5,000 lU
of heparin per liter. Then the system was connected to the subject.
After 10 minutes, a steady state rate of 2 liters of ultrafiltrate per
hour and isovolemic fluid replacement were achieved via a digital
balance control system and a flow-controlled blood roller pump
(AK 10, Gambro AB, Lund, Sweden). A balanced and isotonic
electrolyte solution (HF 03, Fresenius, Bad Homburg, Germany)
was infused through the efferent limb of the extracorporeal system
to maintain zero fluid balance. Low dose heparinization was
performed to prevent filter clotting by adding 300 lU/hr heparin
into the afferent line of the hemofilter. Figure 1 shows the
arrangement of the hemofiltration system.
Collection of plasma and ultrajiltrate
From patients and volunteers, citrate (0.011 mmol/liter) and
EDTA (10 mmol/liter) anticoagulated sterile samples were col-
lected after steady-state conditions of the hemofiltration proce-
dure were reached (t0), and 60 minutes later (t6). Samples were
taken simultaneously from the afferent (pre-hemofilter) line
(proximal to the heparin infusion port), from the efferent (post-
hemofilter) line (post-dilution, distal to the electrolyte infusion
port) and from the ultrafiltrate port (Fig. 1). Immediately after
collection on ice, all plasma tubes were centrifuged at 4°C for 15
minutes, aliquoted under a laminar flow hood and stored at
—80°C until further use. Native ultrafiltrate samples (without
anticoagulant) were used for the cell cultures. These samples had
been kept frozen until use.
Assays
In patients and in healthy volunteers, cytokines and comple-
ment factors were measured in the pre-hemofilter line, in the
post-hemofilter line and in ultrafiltrate at to and t60. One assay was
used to measure all samples from an individual patient or
volunteer. Sieving coefficients were calculated by the formula:
ultrafiltrate concentration/pre-hemofilter concentration. Cyto-
kines were also determined in the supernatants from cell experi-
ments.
Interleukin-6 (IL-6) bioassay. IL-6 activity was determined by
the 7TD1-specific, IL-6 dependent cell line as described previ-
ously [16] with slight modifications. Briefly, cells at a density of
104/ml were cultured in 96-well plates (Falcon, Oxnard, CA,
USA). The viability of 7TD1 cells was tested using 0.5% Tiypan
blue exclusion tests. Serial dilutions of supernatants were incu-
bated in 100 pA RPMI 1640 medium (Gibco, Paisley, UK),
supplemented with 10% fetal calf serum (FCS) (Vitromex,
Vilshofen, Germany) and 0.213 g/liter gentamicin sulfate (Merck,
Darmstadt, Germany) in duplicate for four days at 37°C and in a
6% CO2 air. Then 10 pi tetrazolium salt solution (MIT) (Sigma,
Deisenhofen, Germany) at a concentration of 5 mg/ml were
added. After four hours of incubation the test was stopped with
100 tl of 10% sodium dodecylsulfate (SDS) and incubated
overnight at room temperature. The day after, optical densities,
reflecting the degree of proliferation, were measured using a
micro-ELISA plate reader at 620 nm. One unit of IL-6 was
defined as half maximum growth of the hybridoma cells. Calcu-
lations were done based on a standard curve which had been
obtained from serial dilutions with human recombinant IL-6
(Boehringer, Mannheim, Germany). The slope of the sample
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ultrafiltrate
(2 iiters/hr)
ultrafiltrate
sampling
port
Fig. 1. Arrangement of hemofiltration devices,
lines and ports. Vascular access is performed via
puncture of the femoral or subclavian vein and
by subsequent insertion of a double-lumen
Shaldon catheter. After continuous addition of
heparin (300 IU/hr) into the afferent line of the
hemofilter to prevent filter clotting, venous
blood passes through a flow-controlled roller
pump (pump rate approximately 9 liters/br) and
reaches the hemofilter. There, ultrafiltrate is
generated at a rate of 2 liters/hr by adjusting
the perfusion pressure of the pump.
Subsequently, isovolemic fluid replacement is
achieved by adding the corresponding amount
of substitution fluid into the efferent line of the
hemofilter via a pump-controlled digital balance
system. Blood is recycled back into the body via
the Shaldon catheter. Samples are taken from
the afferent and efferent line of the hemofilter
at the Shaldon catheter, and from the
ultrafiltrate line.
curve was compared to that of the standard. Repeated intra-assay
measurements of one sample gave a coefficient of variation < 5%.
Tumor necrosis factor alpha (TNFa) bioassay. TNFa induced
cytotoxicity was measured using the highly specific fibrosarcoma
cell line WEHI 164 subclone 13 [17]. Briefly, the cells were
cultivated at a concentration of 106/ml in RPM! 1640 medium
supplemented with 10% FCS and 0.5 g/ml actinomycin D
(Sigma, St. Louis, MO, USA), to increase sensitivity of WEHI
cells. After 20 hours incubation the MTT assay was done as
described above. The optical density reflected the degree of
non-lyzed, and therefore, still proliferating cells. Calculations
were done as described above, using serial dilutions of a standard
human rTNFa solution (Genzyme, San Diego, CA, USA) with the
only exception being that one unit of TNFa was defined as
half-maximum cytotoxicity. This bioassay has been shown to be
highly sensitive and specific for TNFa [18].
Interleukin-2 (IL-2) bioassay. The assay for detection of IL-2
activity was done as described previously [19] with slight modifi-
cations. T-cell cultures from one immunologically tested human
volunteer were cultured with Concanavalin A (Sigma) for five
days and then stored frozen in liquid nitrogen (Con A blasts). To
perform the assay, Con A blasts were warmed up, washed and
resuspended with RPM! 1640 medium and tested for viability as
described above. To assess IL-2 release, 100 d aliquots of serially
diluted lymphocyte supernatants were placed in microtiter plates
and 100 l of Con A blasts were added to each well. The final
concentration was 4 X iO cells per well. Cells were also incubated
for 72 hours at 37°C and in a 6% CO2 atmosphere with 15%
serum, 3% highly purified phytohemagglutinin (PHA; Welcome,
Burgwedel, Germany), or 2% Con A as controls. Six hours before
harvesting on glass fiber paper with an automated sample har-
vester, 1 iCi of 3H thymidine per well was added. The uptake of
3H thymidine was counted in a beta-counter and reflected the
proliferation of IL-2-dependent cells. Comparisons of IL-2 activ-
ities were performed using a standard solution of 1 U/ml by
definition (Lymphoccult HP, Biotest, MUnchen, Germany). Units
of IL-2 in supernatants were calculated in comparison with the
standard solution. The percentage of the maximum number of
counts, obtained from the standard, was plotted against the log 2
of dilution. The dilution, when the Lymphoccult preparation
reached 50% of maximum thymidine uptake, was taken consid-
ered one unit.
Interleukin-1/3 (IL-i 13), interleukin-8 (IL-8), C3, C3ad,SA,x and
C5adsA,g assay. Concentrations of IL-1f3, IL-8, C3, C3adesArg and
C5adesArg in plasma, in ultrafiltrate or in supernatants were
determined by using commercially available ELISA kits according
to the manufacturers' instructions (IL-1J3, Immunotech S.A.,
Marseilles, France; IL-8, Amersham, Braunschweig, Germany;
C3, Boehringer; C3adesArg, Progen, Heidelberg, Germany; and
CSadesArg, Behring, Marburg, Germany). The detection limit
reported for IL-1f3 and IL-8 was 5 pg/ml, for C3adesArg, 5 ng/ml
and for CSadesArg, 0.1 ng/ml.
Assay for the terminal complement complex (TCC). TCC concen-
trations in the afferent and efferent blood lines of the hemofilter
were measured by a sensitive and specific micro-ELISA, using a
monoclonal antibody against TCC neoantigen, as described pre-
viously [20].
Cell cultures
PBMC, monocyte and lymphocyte culture studies were per-
formed with ultrafiltrate from patients and healthy volunteers.
Ultrafiltrate effects were analyzed at to and t6. One cell prepara-
tion was always used, to study ultrafiltrate from one patient and
one volunteer. Simultaneous analysis of PBMC, monocyte and
lymphocyte cultures allows differentiation between the effect of
ultrafiltrate on isolated subfractions (monocytes or lymphocytes)
and on the combination of both subfractions (PBMC). Thereby
one can also study the effect of ultrafiltrate on specific cell-to-cell
interactions.
PBMC cultures. Peripheral blood mononuclear cells (PBMC)
were prepared by standard laboratory methods [21]. Approxi-
mately 200 ml peripheral blood from healthy volunteers was
placed in sterile, pyrogen-free and heparinized (20 U/ml) tubes
and diluted (1:2) in Ranks balanced salt solution (HBSS; Gibco,
St. Louis, MO, USA). Standard ficoll hypaque (Biochrom, Berlin,
Germany) density gradient centrifugation (150 g, 30 mm, 4°C) was
then performed. The cells from the interphase were washed three
times with HBSS and resuspended in RPMI. Cell viability was
tested, as described above, and always exceeded 95%.
afferent sampling port
heparin infusion port 300 lU/hr
from patient
to patient 4
efferent sampling port
roller pump (9 liters/br)
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Table 2. IL-1J3, IL-6, IL-8, TNFa, C3adeArg, C3, CSad..Arg, and TCC (terminal complement complex) concentrations in 16 septic patients
IL-1f3
pg/mi
IL-6
U/mi
IL-8
pg/mi
TNFa
U/mi
C3adArg
nglmi
C3
mg/mi
CSadCsArg
ng/ml
TCC
ng/mi
Concentrations in the
afferent line
to 66.02 28.00 1,091 896 1,439 749 33.14 6.04 676.9 99.7 0.723 0.098 26.58 4.71 2,966 663
tso 63.24 24.90 1,127 989 1,447 731 28.55 6.43 545.4 83.2k' 0.728 0.097 25.65 4.39 3,362 804
Ultrafiltrate concentrations
to
t60
11.9 3.72
ND
°
°
630 367
604 292
°
°
140.9 35.9
103.7 25.9°
ND
ND
0.446 0.08
0.183 0036
C
ND
Measurements were performed in plasma samples from the afferent filter line and in ultrafiltrate samples, when a steady state in the hemofiltration
procedure was reached (t0) and 60 minutes later (t60).
ap < 0.01 vs. t0
6 P < 0.005 vs. t)
Not detectable by bioassay; ND, not determined
PBMC cultivation. PBMC were cultivated in 5 ml culture tubes
(Falcon, Oxnard, CA, USA) at a final concentration of 5 X 1O
cells/mi in RPMI supplemented by 7.5% FCS and 0.213 mg/mI
gentamicin sulfate (Merck, Darmstadt, Germany) and stimulated
in duplicate in the presence of: (a) ultrafiltrate only, at an end
concentration of 50%, (b) ultrafiltrate at an end concentration of
50% combined with 1 .tg/ml endotoxin derived from C. parvum
(LPS) (Welcome, London, UK), and (c) isotonic saline solution
(NaCI) at an end concentration of 50% combined with 1 .tg/ml
LPS (control assay). After 20 hours cell suspensions were centri-
fuged at 600 g, and supernatants were immediately frozen at
—80°C until processing. Supernatants were analyzed for TNFa,
IL-6 and IL-1/3 release by the assays described above.
Proliferation tests. PBMC were seeded at 1 X iO cells per well
in triplicate to flat bottomed, 96-well microtiter plates, and 7.5%
FCS and 0.213 mg/ml gentamicin sulfate (Merck) were added.
Three test series were performed in presence of: (a) ultrafiltrate
only, at an end concentration of 25%, (b) ultrafiltrate at a final
concentration of 25% combined with 0.5 g/ml PHA, and (c) in
presence of 25% NaC1 combined with 0.5 .tg/ml PHA. The plates
were incubated at 37°C in 6% CO2 for 72 hours. Cultures were
pulsed with 3H thymidine and harvested as described above.
Activity uptake during four hours was counted on a beta-counter
and reflected cell proliferation.
Monocyte cultures. Two ml of PBMC suspension adjusted to a
concentration of 5 x 106 cells/mi were seeded out in six-well
plates (Greiner, Nurtingen, Germany). Suspensions were incu-
bated for four hours to purify the monocyte population by glass
adherence at 37°C and 6% CO2 in Dulbecco's culture medium
(Gibco) supplemented by 10% FCS [221. Afterwards the super-
natants were removed and the plates were gently washed with
sterile phosphate-buffered saline (PBS). More than 90% of ad-
herent cells were monocytes as indicated by morphological anal-
ysis (non-specific esterase reaction). The monocytes were then
cultivated in FCS (10%) enriched Dulbecco's medium for 20
hours. Three incubation series (50% ultrafiltrate only, 50% ultra-
filtrate combined with LPS, and 50% NaCJ combined with LPS)
were performed in triplicate, as described above. After incuba-
tion, supernatants were collected and frozen at —80°C until assays
were performed. Monocyte supernatants were analyzed for
TNFa, IL-6 and IL-1f3.
Lymphocyte cultures. The non-adherent cells (lymphocytes)
from the monocytes preparation were centrifuged at 200 g for 10
minutes and cultivated after testing of viability by Trypan blue, as
described above. Three incubation series (50% ultrafiltrate only,
50% ultrafiltrate combined with PHA at a final concentration of
2.5 .tg/ml, and 50% NaC1 combined with 2.5 g/ml PHA) were
done as described above. Incubation was performed for 48 hours.
Then cell suspensions were centrifuged at 600 g and supernatants
were frozen at —80°C until processing. Lymphocyte supernatants
were analyzed for IL-2 and IL-6.
Statistics
All data were expressed as mean SEM. The differences
between different incubation procedures (ultrafiltrate vs. NaC1)
and between different time points (t0 vs. t60) were compared with
the Wilcoxon rank test. The multiplicity of comparisons was
accounted for by using a significance level of P = 0.01 throughout
the study.
Results
Concentration of cytokines and complement factors
In septic patients pre-hemofilter (afferent) complement and
cytokine levels at to and t60 were markedly elevated compared to
those of healthy volunteers (Tables 2 and 3). In the latter group,
IL-113, IL-6 and TNFa could not be detected in plasma (Table 3).
During hemofiltration pre-filter (afferent) concentrations of cyto-
kines remained constant in patients, as well as in healthy subjects.
In both groups, however, we observed a significant fall in afferent
C3adesArg concentration (Tables 2 and 3), whereas afferent C3,
CSadesArg and TCC did not change during the first 60 minutes of
continuous veno-venous hemofiltration.
Septic ultrafiltrate contained IL-1/3, IL-8, C3adesg and
CSadesArg (Table 2). Sieving coefficients (SC) of IL-8 and of
C3adcsArg in patients remained constant during hemofiltration
(IL-8, SC at t0: 0.56 0.065 vs. SC at t60: 0.80 0.173, NS;
C3adCSACO, SC at t0: 0.204 0.02 vs. SC at t60: 0.211 0.029, NS).
IL-6, TNFa and the terminal complement complex could not be
detected in septic ultrafiltrate. Ultrafiltrate from volunteers dem-
onstrated small amounts of IL-8, C3adesArg and CSadesArg (Table
3). After 60 minutes of hemofiltration, ultrafiltrate concentrations
of C3adesArg declined in patients and healthy subjects (Tables 2
and 3).
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Table 3. IL-113, IL-6, IL-8, TNFa, C3adesArg, C3, CSadArg, and TCC (terminal complement complex) concentrations in five healthy volunteers
IL-1J3
pg/mi
IL-6
U/mi
IL-8
pg/mi
TNFo
U/mi
C3adesg
ng/ml
C3
mg/mi
CSadg
ng/mi
TCC
ng/mi
Concentrations in the afferent line
to
t60
0
0
C
C
41.20 6.04
31.00 6.04
C
C
54.82 13.25
33.91 0.68"
0.487 0.034
0.495 0.04
9.70 1.60
8.82 1.00
363 153
769 279
Ultrafiltrate concentrations
to
t60
ND
ND
C
C
30.00 2.16
ND
C
C
18.22 1.63
799 j29b NDND 0.552 0.0620.059 0.027a NDND
Measurements were performed in plasma samples from the afferent filter line and in ultrafiltrate samples, when a steady state in the hemofiltration
procedure was reached (t0) and 60 minutes later (t50).
aP < 0.01 vs. to
b P < 0.005 vs. to
C Not detectable by bioassay; ND, not determined
Table 4. TNFa, IL-6 and IL-1/3 release of human peripheral blood mononuclear cells (PBMC) in vitro
Septic patients (N = 16) Healthy volunteers (N = 5)
Ultrafiltrate
at to
Ultrafiltrate
at t60
NaCI
controls
Ultrafiltrate
at to
Ultrafiltrate
at t60
NaCl
controls
TNFs U/mi
IL-6 U/mi
IL-1f3pg/mi
41.0 lo.oa
2,015 466
966 256
40.2 10.7a
1,485 244
ND
12.8 4.3
2,006 255
946 183
26.5 8.6
1,518 212
935 211
31.2 12.1
1,471 294
ND
23.8 7.8
1,398 175
936 173
All PBMC were co-stimulated with endotoxin (LPS). Cells were incubated with septic or healthy ultrafiltrate collected, when a steady state in the
hemofiltration procedure was achieved (t0) and 60 minutes later (t60). Ultrafiltrate and corresponding NaC1 incubations were always performed in the
same cell preparation.
C P < 0.00 1 vs. NaCI
ND is not determined.
Table 5. TNFa, IL-6 and IL-1/3 release of human monocytes separated by glass adherence in vitro
Septic patients (N = 16) Healthy volunteers (N = 5)
Ultrafiltrate
at to
Ultrafiltrate
at t60
NaC1
controls
Ultrafiltrate
at to
Ultrafiltrate
at t60
NaC1
controls
TNFa U/mi
IL-6 U/mi
IL-113 pg/mi
23.5 39
709 191
334 157
25.0 5.8a
571 149
ND
16.3 4.1
1,568 331
407 185
18.0 4.9
800 231
401 182
22.3 4.6
918 209
ND
21.4 4.0
1,079 364
456 202
All monocytes were co-stimulated with endotoxin (LPS). Cells were incubated with septic or healthy ultrafiltrate collected, when a steady state in the
hemofiltration procedure was achieved (t0) and 60 minutes later (t60). Ultrafiltrate and corresponding NaCI incubations were always performed in the
same cell preparation.
ap < 0.001 vs. NaCI
ND is not determined.
No pre/post-filter concentration differences in cytokines were
detected in patients or in volunteers at to or t60. Also pre/post-
filter concentrations of the terminal complement complex did not
change significantly during hemofiltration in patients (t0, pre-
filter, 2,966 663 ng/ml, and post-filter, 3,429 710, NS; t60,
pre-filter 3,362 804 ng/ml, and post-filter, 3,961 678, NS) and
in volunteers (t0, pre-filter, 363 153 ng/ml, and post-filter, 598
133, NS; t60, pre-filter, 769 279 ng/ml, and post-filter, 1,215
442, NS).
Cell culture experiments
Peripheral blood mononuclear cell cultures (Table 4). Septic or
healthy ultrafiltrate per se did not alter cell function in comparison
to NaCI control experiments (data not shown). Reproducible
changes in PBMC and monocyte cultures (see below) occurred
only when PBMC cultures were incubated with ultrafiltrate and
LPS.
Septic ultrafiltrate produced a significant rise at to and t60 in
TNFa release in LPS-stimulated PBMC when compared to
LPS-stimulated NaCl controls. PBMC did not respond to healthy
ultrafiltrate. IL-6 and IL-113 release was not affected by either
healthy or septic ultrafiltrate in comparison to NaCI controls.
PBMC proliferation. PBMC thymidine uptake was significantly
suppressed compared to NaCl when septic ultrafiltrate was incu-
bated with PHA-stimulated PBMC (ultrafiltrate from septic pa-
tients, 14,754 1,534 cpm, and NaC1, 37,418 160 cpm, P <
0.01; ultrafiltrate from volunteers, 27,744 2,653 cpm, and NaC1,
32,856 228 cpm, NS). Only ultrafiltrate at to was used.
Monocyte cultures stimulated with LPS (Table 5). Septic ultrafil-
trates from to and t60 significantly accelerated the TNFa release
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Table 6. IL-2 and IL-6-release of human lymphocytes separated by glass adherence in vitro
Septic patients (N = 16) Healthy volunteers (N = 5)
Ultrafiltrate Ultrafiltrate NaCI Ultrafiltrate Ultrafiltrate NaCI
at to at t60 controls at to at t60 controls
IL-2 LI/mI 0.35 0.07k ND 0.66 0.07 0.48 0.18 ND 0.41 0.12
IL-6 U/mi 4,295 896 3,093 74l 6,496 873 5,879 2,670 5,316 1,833 5,433 1,497
All lymphocytes were co-stimulated with phytohemagglutinin (PHA). Cells were incubated with septic or healthy ultrafiltrate collected, when a steady
state in the hemofiltration procedure was achieved (t0) and 60 minutes later (t60). Ultrafiltrate and corresponding NaCI incubations were always
performed in the same cell preparation.
aP < 0.00 1 vs. NaCI
bp < 0.001 vs. NaCl.
ND is not determined.
from monocytes and suppressed their IL-6 release in comparison
to NaCI controls. Monocytes incubated with ultrafiltrate from
volunteers showed no response compared to NaC! controls and no
change in IL-113 release when incubated with either healthy or
septic ultrafiltrate.
Lymphocyte cultures stimulated with PI-L4 (Table 6). IL-2 and
IL-6 release from lymphocytes decreased significantly after incu-
bation with septic ultrafiltrate in comparison to NaC1 controls.
Healthy ultrafiltrate remained without effect on lymphocytes'
cytokine release.
Discussion
According to a recent consensus conference, all patients in the
present study were suffering from a multiple organ dysfunction
syndrome [14]. Multiple organ dysfunction syndrome is thought to
be a result of a self-enhancing generalized reaction mediated by
several cascade systems. It is likely that the pathogenesis and
pathophysiology of various clinical entities that comprise the
multiple organ dysfunction syndrome are similar. Several types of
mediators, such as cytokines or complement factors, which play a
role in the pathophysiology of sepsis were identified in the past
[12]. In the present study, we wanted to test the hypothesis that
hemofiltration could eliminate some of these mediators, thereby
rendering continuous veno-venous hemofiltration useful as an
immunomodulatory strategy in critical care medicine, indepen-
dent of hemofiltration's importance in renal replacement therapy.
We found that, among the commonly known cytokines and
complement factors, hemofiltration may eliminate IL-13, IL-8,
C3adesArg and CSadesArg, but not TNFa and IL-6, in patients with
systemic inflammatory response syndrome. Septic ultrafiltrate
contains a mixture of mediators which stimulates TNFs produc-
tion in PBMC and in monocyte fractions, and which suppresses
IL-2 and IL-6 synthesis in lymphocytes.
When hemofiltration is tested as a tool to eliminate mediators
of the multiple organ dysfunction syndrome, the possibility that
the procedure itself causes substantial mediator activation by
blood-hemofiltration membrane contact must be excluded. Our
results show this phenomenon to be unlikely.
Firstly, hemofiltration in volunteers produced an ultrafiltrate
which contained far lower concentrations of established mediators
than did septic ultrafiltrate, and in which certain mediators, such
as IL-1/3, were absent. Furthermore, healthy ultrafiltrate, unlike
septic ultrafiltrate, did not change white blood cell function.
Secondly, neither volunteers nor patients with a multiple organ
dysfunction syndrome showed signs of an hemofiltration-induced
activation of the complement system, a hallmark characteristic of
bio-incompatible membranes [1, 23], which can be tested by
measuring concentrations of the terminal complement complex
[20]. According to recent studies, bio-incompatibility is reflected
by a rise in pre- and post-filter (afferent and efferent) concentra-
tions of the terminal complement complex and by a rise in the
concentration difference of the terminal complement complex
across the filter, even during short term treatment [1, 20]. With
the hemofiltration procedure used in our study, we observed no
such increases in patients or in volunteers. Substantial activation
of the complement system is also made unlikely by the finding that
C3adesArg concentrations decreased during hemofiltration, indi-
cating even elimination of complement factors. Besides, concen-
trations of the terminal complement complex in the plasma from
our healthy volunteers did not differ from concentrations in the
plasma from healthy non-treated subjects [20].
Therefore, it is safe to conclude that the mediators present in
ultrafiltrate are indeed eliminated from the critically ill organism,
but their exact nature and quality are unknown. However, a few
general comments are possible. The membranes which were
developed for hemofiltration, demonstrate high permeability in
the so-called middle molecule range, such as for f32-microglobulin,
which has a molecular weight of 11.815 kD [24]. In vitro studies,
which used dextran and proteins of various sizes, identified a
cut-off point of about 30 kD in polyamide membranes such as ours
[24]. However, this finding does not necessarily mean that all
compounds with molecular weights below 30 kD can be removed
via hemofiltration since other variables such as molecular struc-
ture, electric charges, hydrophilicity and hydrophobicity, the
presence of plasma antagonists, receptor binding of compounds,
and filtration modalities (such as transmembrane pressure) have
been shown to be important determinants for the efficacy of
compound filtration [24]. The complex mechanism of compound
removal is illustrated by the fact that IL-6 could not be detected
in ultrafiltrate from septic patients, although its biologically active
monomer form has a molecular weight of 26 kD [25], and large
amounts of active IL-6 were found in septic plasma (Table 2).
Presumably, a different mechanism than molecular weight exclu-
sion (such as binding to the plasma protein a2-macroglobulin
[26]) must have been responsible for the absent IL-6 filtration.
In contrast, molecular weight explains why IL-113 and IL-8, but
not TNFcs, appeared in ultrafiltrate from patients. TNFa, in its
active form, is a trimer, with an estimated molecular weight of 51
kD [25]. A molecule of this size is not expected to be eliminated
via hemofiltration. Our finding corresponds to in vitro experiments
which used Iipopolysaccharide-induced active TNFa, and which
did not detect TNFs in the filtrate compartment, even when a
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highly permeable polyacrylonitrile membrane was used [27].
Correspondingly, we and others [9, 11] could not measure a
change in pre-filter TNFa concentration during hemofiltration.
Recent conflicting results, which showed a substantial clearance of
TNFa by hemofiltration in clinical sepsis [11, 28] or in in vitro
hemofiltration [29], may be explained by differences in the TNFa
assay used. Thus, ELISA procedures may also measure smaller,
biologically inactive, split products (monomeric forms) of the
biologically active TNFa molecule.
IL-1J3 (molecular wt 17 kD) and IL-8 (molecular wt 8 kD) could
be detected in ultrafiltrate. Filtration of IL-1f3 has also been
shown during in vitro hemofiltration [29]. However, in our studies
pre- and post-filter concentrations of these cytokines remained
constant during hemofiltration. This corresponds to recent studies
performed in septic patients [11, 28] and may be explained by two
phenomena. Firstly, the variability of the cytokine assays used may
have been too large to allow detection of small concentration
differences over time and, secondly, the elimination rate of both
cytokines may have been far below their corresponding produc-
tion rate. If one assumes a rough half life for plasma IL-113 of
three minutes [30], a plasma volume of 3 liter and a constant
plasma concentration of 60 pg/mi, then approximately 1.8 g of
plasma IL-113 will be produced per hour. On the other hand, with
an IL-1/3 ultrafiltrate concentration of 11.9 pg/ml and a filtration
rate of 2 liter/hr, about 24 ng of IL-lp will be eliminated per hour.
This is only about 1.5% of the roughly estimated plasma produc-
tion rate, and thus an elimination rate of IL-lp and presumably
also of IL-8 must be considered too small to be of significant
biologic importance. Obviously, this statement cannot necessarily
be extended to other still unknown cytokines or pro-inflammatory
peptides.
In contrast to the examined cytokines, we found evidence of the
important elimination of complement factors by hemofiltration,
during which pre-filter C3adesArg concentrations decreased signif-
icantly in patients, but also in healthy volunteers (Tables 2 and 3).
C3adesArg (molecular wt 9 kD) and C5adesArg (molecular wt 11
kD) could both be identified in septic and healthy ultrafiltrate.
This observation is in line with results of a recent study which
showed C3adesg elimination after cardiopulmonary bypass by a
hemofiltration procedure using a polyamide membrane similar to
the membrane we used [31]. CSadesArg concentrations did not
change during the first 60 minutes of hemofiltration, but effective
elimination of CSadesArg may have been delayed due to its rapid
binding to cellular receptors [20]. Preliminary results from our
institution show that longer periods of hemofiltration may not
only lead to a further decrease of plasma C3adesg, but also of
CSadesArg [32]. Reduction of anaphylatoxin concentration could
be of clinical importance, since beneficial therapeutic effects in
sepsis have been correlated with a fall of anaphylatoxin concen-
trations [13, 33].
At present, we cannot describe the exact nature of all mediators
removed by hemofiltration and the individual biological signifi-
cance of their removal. However, it appeared feasable to evaluate
the biological effects of the ultrafiltrate as a whole by exposing
several peripheral mononuclear blood cell subfractions to ultra-
filtrate in vitro.
A key finding from the incubation experiments was that septic,
but not healthy ultrafiltrate, stimulated TNFa release in the
PBMC and in the monocyte fraction (Tables 4 and 5). The exact
mechanism of ultrafiltrate-stimulated TNFa release cannot be
determined by our experiments. Involvement of endotoxin is
unlikely, since it will be rejected by the hemofiltration membrane
by molecular size exclusion (molecular wt about 100 kD) [34].
However, C3adesArg and possibly also interferon y (molecular wt
20 kD) could be potential mediators of the TNFa effect, as they
may stimulate TNFa production in vitro in PBMC and monocyte
cell cultures [35, 36].
Besides its stimulating qualities, septic ultrafiltrate also demon-
strated a variety of suppressive effects. Thus, ultrafiltrate pre-
vented the secondary rise of IL-1/3 release in PBMC and mono-
cyte fractions, which is usually observed as a consequence of
enhanced TNFa release [37]. The mechanism of this down
regulation is unknown. Furthermore, septic ultrafiltrate effectively
suppressed IL-6 release in monocytes (see above), and IL-6 and
IL-2 release in lymphocytes. This ultrafiltrate-related suppressive
effect indicates a significant impairment in lymphocyte function
(IL-6 release and IL-2 release are sensitive markers for lympho-
cyte protein synthesis [38]) and corresponds to findings in criti-
cally ill patients whose lymphocytes demonstrated a decreased
IL-2 release [38] and proliferation rate [39], and whose monocytes
showed a reduced IL-6 production [22]. A fall in IL-2 synthesis of
lymphocytes can also explain why septic ultrafiltrate down-regu-
lated the PHA-induced PBMC proliferation.
The mediators of lymphocyte suppression are not completely
elucidated yet. A possible candidate could be prostaglandin E2,
which has a molecular weight of < 0.6 kD. Recent data suggest
that arachidonic acid derivatives may appear in ultrafiltrate [9].
Prostanoids have been implicated in the suppression of the
cell-mediated immune system (including IL-6 and IL-2 release)
[38].
In conclusion, short-term hemofiltration with a highly biocom-
patible, polyamide membrane in patients with septic multiple
organ dysfunction syndrome, does not seem to cause additional
significant activation of mediators, known to be involved in the
pathophysiology of these clinical conditions. This finding contrasts
with the use of cellulosic membranes which have been shown to
result in a significant activation of inflammatory mediators and in
higher mortality rates due to septic complications [40]. Hemofil-
tration with synthetic membranes (such as polyamide membranes)
may even eliminate a variety of mediators from septic plasma.
Filtration of the classic cytokines IL-lp and TNFa is presumably
of minor importance, but clearance of other components such as
complement factors, arachidonic acid derivatives [9], or granulo-
cyte inhibitory peptides [41], could achieve clinical significance,
since these compounds are most likely involved in the develop-
ment of fatal septic complications. The mixture of mediators in
septic ultrafiltrate provokes a stimulation of PBMC and mono-
cytes, with respect to TNFr synthesis, and a suppression of
lymphocyte function. Therefore, hemofiltration might be of po-
tential benefit for patients with multiple organ dysfunction syn-
drome in situations calling for attenuation of monocytic TNFa
release and stimulation of lymphocyte function. This view is
supported by recent investigations in which isovolemic hemofil-
tration improved specific organ failure in septic animals [6—8] and
increased survival rate in critically ill patients with acute renal
failure [4]. Removal of certain mediators via hemofiltration may
represent a new therapeutic concept for patients with multiple
organ dysfunction syndrome.
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